Lineage Cell Therapeutics, Inc. Severance Costs
Lineage Cell Therapeutics, Inc. (LCTX) reported Severance Costs of $700.00 thousand for the 12-month period ending 2020-12-31, per its 10-K filed 2021-03-11.
Discontinued › Expense Statement › Operating Expenses
us-gaap:SeveranceCosts1 · last filed 2021-03-11
- Lineage Cell Therapeutics, Inc. severance costs for the quarter ending 2020-12-31 was $0.00.
- Lineage Cell Therapeutics, Inc. severance costs for the quarter ending 2020-09-30 was $0.00, a 100.00% decline year-over-year.
- Lineage Cell Therapeutics, Inc. severance costs for the quarter ending 2020-06-30 was $0.00.
- Lineage Cell Therapeutics, Inc. severance costs for the quarter ending 2020-03-31 was $700.00K.
- Lineage Cell Therapeutics, Inc. severance costs for fiscal 2020 was $700.00K, a 0.00% change from fiscal 2019.
- Lineage Cell Therapeutics, Inc. severance costs for fiscal 2019 was $700.00K.
| Period end | Severance Costs 3 month | Severance Costs 6 month | Severance Costs 9 month | Severance Costs 12 month |
|---|---|---|---|---|
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-11 | $0.00 derived: sum of 2 quarters · filed 2021-03-11 | $0.00 derived: sum of 3 quarters · filed 2021-03-11 | $700.00K 10-K · filed 2021-03-11 |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-04 | $0.00 derived: sum of 2 quarters · filed 2020-11-04 | $700.00K 10-Q · filed 2020-11-04 | $700.00K derived: sum of 4 quarters · filed 2020-11-04 |
| 2020-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | $700.00K 10-Q · filed 2020-08-06 | $700.00K derived: sum of 3 quarters · filed 2020-08-06 | $900.00K derived: sum of 4 quarters · filed 2020-08-06 |
| 2020-03-31 | $700.00K 10-Q · filed 2020-05-07 | $700.00K derived: sum of 2 quarters · filed 2020-05-07 | $900.00K derived: sum of 3 quarters · filed 2020-05-07 | |
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-12 | $200.00K derived: sum of 2 quarters · filed 2020-03-12 | $700.00K 10-K · filed 2020-03-12 | |
| 2019-09-30 | $200.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-12 | $700.00K 10-Q · filed 2019-11-12 | ||
| 2019-06-30 | $500.00K 10-Q · filed 2019-08-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |